Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Gains from Sales and Divestitures (2017 - 2025)

Historic Gains from Sales and Divestitures for Rocket Pharmaceuticals (RCKT) over the last 7 years, with Q3 2025 value amounting to $825320.0.

  • Rocket Pharmaceuticals' Gains from Sales and Divestitures rose 4030.88% to $825320.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $825320.0, marking a year-over-year increase of 4030.88%. This contributed to the annual value of $722471.0 for FY2024, which is 7702.46% up from last year.
  • Latest data reveals that Rocket Pharmaceuticals reported Gains from Sales and Divestitures of $825320.0 as of Q3 2025, which was up 4030.88% from $478289.0 recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Gains from Sales and Divestitures registered a high of $825320.0 during Q3 2025, and its lowest value of $10168.0 during Q1 2022.
  • For the 4-year period, Rocket Pharmaceuticals' Gains from Sales and Divestitures averaged around $315966.1, with its median value being $300068.0 (2025).
  • Per our database at Business Quant, Rocket Pharmaceuticals' Gains from Sales and Divestitures soared by 287276.75% in 2023 and then surged by 326.59% in 2025.
  • Over the past 4 years, Rocket Pharmaceuticals' Gains from Sales and Divestitures (Quarter) stood at $38966.0 in 2022, then skyrocketed by 947.37% to $408119.0 in 2023, then soared by 77.02% to $722471.0 in 2024, then grew by 14.24% to $825320.0 in 2025.
  • Its last three reported values are $825320.0 in Q3 2025, $478289.0 for Q2 2025, and $300068.0 during Q1 2025.